MENU
AIM ImmunoTech (AIM) Ownership - Who owns AIM ImmunoTech?
Profile
Industry
N/A
Address
2117 SW Highway 484
Phone
+1 352 448-7797
Employees
28
Web
https://www.aimimmuno.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
18.92M
P/E Ratio
N/A
Total Cash
10.06M
Projected Growth
N/A
Total Debt
3.36M
Revenue
201K
Risk (Beta)
1.20
Dividend Yield
N/A
Total Cash/Share
0.18
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
AIM
Capitalization
18.9M
P/E Ratio
N/A
Risk (Beta)
1.20
Dividend Yield
N/A
Total Cash
10.1M
Total Cash/Share
0.18
Total Debt
3.36M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
201K
ROE
N/A
Book Value
6.1M
P/B Ratio
3.10
Cash Flow
N/A
Earnings
-0.57
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
57K
Current Ratio
1.17
Current Revenue Per Employee
1785.71
Dividends Per Share - Security
N/A
EBITDA
-30.52M
Float
N/A
Float - Current
N/A
Gross Income Margin
84.00
Revenue To Assets
-113.70
Shares Held By Institutions
3.82M
Shares Outstanding - Current
57.1M
Total Liabilities
9.61M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-24.733
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
2117 SW Highway 484
Phone
+1 352 448-7797
Employees
28
Web
https://www.aimimmuno.com